23andMe cuts 40% of its workforce and discontinues therapeutics division
NEW YORK (AP) — 23andMe is laying off 40% of its workforce, or more than 200 employees, and discontinuing its therapeutics division as the struggling genetic testing company attempts to slash costs. The latest restructuring efforts were announced by 23andMe on Monday.
23andMe cuts 40% of its workforce
Genetics testing company 23andMe is trimming its headcount by 40%. The company said it is undergoing a restructuring to "streamline operations and reduce costs."
23andMe cuts 40% of its workforce, discontinues all therapy programs
The company said it is evaluating strategic alternatives, including licensing agreements and asset sales, for its therapies in development.
23andMe Lays Off 40 Percent of its Staff, Ends All Therapy Programs
As founder and CEO Anne Wojcicki struggles to take the company private, 200 jobs are cut as part of its restructuring plan.
23andMe to cut 40% of workforce, end therapeutics program
Genetic-testing lab 23andMe plans to cut its workforce by 40% and end its therapeutics program in an effort to cut costs, the company announced Monday.
23andMe to reduce overall headcount by 40% of workforce
Holding “announced a business restructuring to streamline operations and reduce costs. In addition, 23andMe is discontinuing
23andMe to slash 40% of its workforce, end therapeutics program to cut costs
DNA-testing company 23andMe Holding Co. will slash its workforce by about 40% and discontinue its therapeutics program as part of a restructuring effort to cut costs, the company said Monday.
23andMe to lay off 40% of its workforce as stock price plummets
The genetic testing company 23andMe is cutting 40% of its workforce and ending its therapeutics program as its stock price continues to plummet. CBS News correspondent Carter Evans has more on what this means for its customers.
Hosted on MSN19h
After its entire board resigned overnight, 23andMe will cut over 200 employees and its cancer research in an urgent bid to nurse the company back to health
DNA-testing service 23andMe is making substantial efforts to nurse its feeble genetic core back to health. The company will ...
23andMe is ending its cancer research program and slashing over 200 jobs
23andMe is laying off 40 percent of its employees, or over 200 workers, as the company attempts to recover from last year’s ...
23andMe reports sales decline day after announcing plans to cut 40% of workforce
Embattled genetic testing provider 23andMe said on Tuesday that revenue declined from a year earlier, a day after the company ...
23andMe to lay off 40% of staff in desperate restructuring effort
Home genetics company 23andMe continues to struggle as demand for casual gene tracing declines. On Monday, the company ...
23andMe Reports Improved Financial Metrics Amid Revenue Decline
Andme Holding Co ( (ME) ) has released its Q2 earnings. Here is a breakdown of the information 23Andme Holding Co presented to its investors.
23andMe Lays Off 40% of Its Workforce as Company Spirals
The genetic testing company 23andMe announced it was laying off more than 200 employees, or roughly 40% of its entire ...
Yahoo13h
What happens to customer data as 23andMe goes out of business?
Millions of people have sent their DNA to be analyzed by 23andMe in order to learn their genealogy and risk for certain ...
Yahoo Finance14m
Struggling Genetic Testing Company 23andMe To Lay Off 40% Of Its Workforce, Discontinues All Therapeutic Programs
On Thursday, genetics-led consumer healthcare company 23andMe Holding Co. (NASDAQ:ME) announced a business restructuring to ...
NBC Los Angeles1d
23andMe reports sales decline a day after announcing plans to cut 40% of workforce
23andMe on Tuesday reported that second-quarter revenue fell to $44.1 million from $50 million a year earlier. The ...
The Hindu57m
If 23andMe goes bust, what happens to its DNA database?
Since it was founded nearly two decades ago, 23andMe has grown into one of the largest biotechnology companies in the world ...